Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00686959
Registration number
NCT00686959
Ethics application status
Date submitted
28/05/2008
Date registered
30/05/2008
Date last updated
28/06/2016
Titles & IDs
Public title
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Query!
Scientific title
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Query!
Secondary ID [1]
0
0
H3E-MC-JMIG
Query!
Secondary ID [2]
0
0
11514
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PROCLAIM
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Pemetrexed
Treatment: Drugs - Cisplatin
Treatment: Drugs - Etoposide
Treatment: Drugs - Vinorelbine
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Carboplatin
Experimental: Arm A: Pemetrexed + Cisplatin and TRT - Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) ("Concurrent Phase") for three 21-day cycles, followed by a 3-5 week "Recovery Period," then treated with consolidation chemotherapy with pemetrexed ("Consolidation Phase") for up to four 21-day cycles
Concurrent Phase:
Pemetrexed: 500 milligrams per meter squared (mg/m\^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.
Cisplatin: 75 mg/m\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray \[Gy\] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.
Consolidation Phase:
Pemetrexed: 500 mg/m\^2, IV on Day 1 of each 21-day cycle up to 4 cycles
Active comparator: Arm B: Etoposide + Cisplatin and TRT - Participants were treated with Etoposide plus Cisplatin and concurrent TRT ("Concurrent Phase") for two 28-day cycles, followed by a 3-5 week "Recovery Period," then received consolidation treatment with cytotoxic chemotherapy of choice ("Consolidation Phase") for up to 2 cycles
Concurrent Phase:
Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\^2, IV on Days1, 8, 29, and 36
Consolidation Phase options:
Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22
Treatment: Drugs: Pemetrexed
infusion over 10 minutes
Treatment: Drugs: Cisplatin
infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
Treatment: Drugs: Etoposide
administered per local practice guidelines over a minimum of 30 minutes
Treatment: Drugs: Vinorelbine
administered over 6-10 minutes infusion per local practice guidelines
Treatment: Drugs: Paclitaxel
administered as a 3-hour infusion
Treatment: Drugs: Carboplatin
administered per local practice guidelines over 30 minutes
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival (OS) time is from baseline to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS time was censored at the last contact date the participant was known to be alive prior to the data cut-off date. OS was summarized using Kaplan-Meier estimates.
Query!
Timepoint [1]
0
0
Baseline to Date of Death from Any Cause (Up to 71.4 Months)
Query!
Secondary outcome [1]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [1]
0
0
Progression-free survival (PFS) time is from baseline to the first date of documented objective progressive disease (PD) or death from any cause. For participants who were not known to have died or to have had objective PD as of the data inclusion cut-off date for a particular analysis, PFS was censored at the date of the last objective progression-free disease assessments. For participants who took any subsequent systemic anticancer therapy prior to progression or death, PFS was censored at the date of the last objective progression-free disease assessment prior to the start date of any subsequent systemic anticancer therapy. PFS time was summarized using Kaplan-Meier estimates.
Query!
Timepoint [1]
0
0
Baseline to Measured Progressive Disease or Death from Any Cause (Up to 66.6 Months)
Query!
Secondary outcome [2]
0
0
Objective Response Rate (Complete Response [CR] + Partial Response [PR])
Query!
Assessment method [2]
0
0
Overall response rate (ORR) is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) guidelines. CR is defined as the disappearance of all target and non-target lesions, normalization of tumor marker level of non-target lesions, and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm). PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
Query!
Timepoint [2]
0
0
Baseline to Measured Progressive Disease (Up to 7 Months)
Query!
Secondary outcome [3]
0
0
Survival Rates at 1, 2, and 3 Years
Query!
Assessment method [3]
0
0
The probability that survival time is at least 1, 2, or 3 years was summarized using Kaplan-Meier estimates.
Query!
Timepoint [3]
0
0
Baseline to Date of Death from Any Cause (Up to 71.4 Months)
Query!
Secondary outcome [4]
0
0
First Site of Disease Failure in Terms of Relapse
Query!
Assessment method [4]
0
0
The percentage of participants with first sites of disease failure in terms of relapse within the radiation treatment field, inside the thorax, (outside of the radiation field), or distant disease are presented. Results were summarized using Kaplan-Meier estimates. Some participants relapsed in more than 1 location/site and appear in more than a single category.
Query!
Timepoint [4]
0
0
Baseline to Relapse (Up to 66.6 Months)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With a Post Baseline Swallowing Diary Score >=4
Query!
Assessment method [5]
0
0
Participants were provided with a swallowing diary to record issues with swallowing using a 5-point categorical scale: (1) no problems; (2) mild soreness; (3) swallowing solids with some difficulty; (4) inability to swallow solids; and (5) inability to swallow liquids. Participants rated swallowing over the previous 24 hours. The percentage of participants was calculated by dividing the number of with a post baseline swallowing diary score \>=4 by total number of participants analyzed, multiplied by 100. No adjustments were made for the number of available assessments nor were any interpolation of missing assessments made.
Query!
Timepoint [5]
0
0
Baseline through 30 Days Post Study
Query!
Eligibility
Key inclusion criteria
* Participants must have Stage IIIA or IIIIB NSCLC of the non-squamous type
* Participants must have measureable tumor lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines or disease that can be evaluated on computerized tomography (CT) scan
* Participants must be physically mobile, take care of themselves and must be up and about and able to perform light activities, such as light housework or office work
* Participants must be 18 years of age or older
* Participants must have lost no more than 10% of their body weight in the previous 3 months
* Women must be sterile, postmenopausal, or on contraception, and men must be sterile or on contraception
* Participants' test results assessing the function of their blood forming tissue, kidneys, liver, and lungs must be satisfactory
* Participants with Stage IIIB NSCLC who have supraclavicular nodal involvement may be entered into this study. However, participants with cervical nodes are not permitted. The upper border of supraclavicular nodes must not extend above the upper border of the lateral end of the clavicle, extended medially.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Participants cannot have other on-going (uncontrolled) illnesses, including active infections, recent heart problems, or psychiatric illnesses
* Participants who are unable to take vitamins (including injections of vitamin B12) or oral cortisone medication
* Participants who have had a heart attack (myocardial infarction) or other cardiac issues within 6 months of the trial
* Participants who have received other investigational drugs within the last 30 days
* Participants who are unable to stop taking more than 1.3 grams of aspirin on a daily basis or non-steroidal anti-inflammatory agents
* Participants who have diseases considered for surgical treatment as part of their care plan, such as Pancoast or superior sulcus tumors
* Participants who had prior thoracic radiation. However, other prior radiotherapy is allowed. Participants must have recovered from the toxic effects of the treatment prior to study enrollment. Participants may not have received whole pelvis radiation or radiation to more than 25% of their bone marrow. Prior radiotherapy must have been completed at least 30 days prior to study treatment.
* Participants who have a radiation treatment plan that would expose more than 35% of the volume of their lung to 20 gray (Gy) or more of radiation
* Participants who have concurrent cancer from another primary site requiring treatment of any kind within the past 5 years. Exemptions to this will be permitted on a case-by-case basis after prior approval by the Sponsor physician or designate if the investigator believes the participant's risk of recurrence and death is very low. Curatively treated nonmelanoma skin cancer or in situ carcinoma of any origin is allowed. Participants with recurrence of a previously resected lung cancer or who have a second primary lung cancer are ineligible.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
598
Query!
Recruitment in Australia
Recruitment state(s)
NSW,TAS,VIC
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Wollongong
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Launceston
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Frankston
Query!
Recruitment postcode(s) [1]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [2]
0
0
7250 - Launceston
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Dakota
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
South Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Vermont
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Washington
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
West Virginia
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Wisconsin
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Buenos Aires
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Antwerp
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Edegem
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Gent
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Gilly
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Haine-St.- Paul
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Leuven
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Namur
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Turnhout
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Barretos
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
Curitiba
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Porto Alegre
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
Rio De Janeiro
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
São Paulo
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Alberta
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Ontario
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Quebec
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Beijing
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Guang Zhou
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Jinan
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Shanghai
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Sichuan
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Wu Han
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Bayonne
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Lille
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Paris
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Pierre Benite
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Erlangen
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Frankfurt
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Hannover
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Hemer
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Immenhausen
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Köln
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Mainz
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Mannheim
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Oldenburg
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Rheine
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Ulm
Query!
Country [65]
0
0
Greece
Query!
State/province [65]
0
0
Athens
Query!
Country [66]
0
0
Greece
Query!
State/province [66]
0
0
Patras
Query!
Country [67]
0
0
India
Query!
State/province [67]
0
0
Bangalore
Query!
Country [68]
0
0
India
Query!
State/province [68]
0
0
Hyderabaad
Query!
Country [69]
0
0
India
Query!
State/province [69]
0
0
Jaipur
Query!
Country [70]
0
0
India
Query!
State/province [70]
0
0
Kolkata
Query!
Country [71]
0
0
India
Query!
State/province [71]
0
0
Madurai
Query!
Country [72]
0
0
India
Query!
State/province [72]
0
0
Mumbai
Query!
Country [73]
0
0
India
Query!
State/province [73]
0
0
Trivandrum
Query!
Country [74]
0
0
Ireland
Query!
State/province [74]
0
0
Dublin
Query!
Country [75]
0
0
Korea, Republic of
Query!
State/province [75]
0
0
Incheon
Query!
Country [76]
0
0
Korea, Republic of
Query!
State/province [76]
0
0
Seoul
Query!
Country [77]
0
0
Korea, Republic of
Query!
State/province [77]
0
0
Suwon-City
Query!
Country [78]
0
0
Netherlands
Query!
State/province [78]
0
0
Amsterdam
Query!
Country [79]
0
0
Netherlands
Query!
State/province [79]
0
0
Breda
Query!
Country [80]
0
0
Netherlands
Query!
State/province [80]
0
0
S-Hertogenbosch
Query!
Country [81]
0
0
Portugal
Query!
State/province [81]
0
0
Lisbon
Query!
Country [82]
0
0
Portugal
Query!
State/province [82]
0
0
Santa Maria Da Feira
Query!
Country [83]
0
0
Portugal
Query!
State/province [83]
0
0
Vila Franca De Xira
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Alicante
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Badalona
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Elche
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Hospitalet De Llobregat
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Madrid
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Majadahonda
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Pamplona
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Terrassa
Query!
Country [92]
0
0
Taiwan
Query!
State/province [92]
0
0
Kaohsiung
Query!
Country [93]
0
0
Taiwan
Query!
State/province [93]
0
0
Kuei Shan Hsiang
Query!
Country [94]
0
0
Taiwan
Query!
State/province [94]
0
0
Taichung
Query!
Country [95]
0
0
Taiwan
Query!
State/province [95]
0
0
Taipei
Query!
Country [96]
0
0
Turkey
Query!
State/province [96]
0
0
Fatih
Query!
Country [97]
0
0
Turkey
Query!
State/province [97]
0
0
Gaziantep
Query!
Country [98]
0
0
Turkey
Query!
State/province [98]
0
0
Izmir
Query!
Country [99]
0
0
Turkey
Query!
State/province [99]
0
0
Melikgazi
Query!
Country [100]
0
0
Turkey
Query!
State/province [100]
0
0
Umuttepe
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Birmingham
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Greater London
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Scotland
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00686959
Query!
Trial related presentations / publications
Govindan R, Senan S, Dickgreber N, Provencio M, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, San Antonio B, Winfree K, Vokes EE. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Curr Med Res Opin. 2019 Oct;35(10):1761-1767. doi: 10.1080/03007995.2019.1623185. Epub 2019 Jul 5. Brade AM, Wenz F, Koppe F, Lievens Y, San Antonio B, Iscoe NA, Hossain A, Chouaki N, Senan S. Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):927-934. doi: 10.1016/j.ijrobp.2018.04.015. Epub 2018 Apr 12.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00686959
Download to PDF